Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Novocure

< Previous 1 2 3 4 Next >
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Tickers NVCR
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
From Novocure
Via Business Wire
Tickers NVCR
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports Third Quarter 2023 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
From Novocure
Via Business Wire
Tickers NVCR
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Report Third Quarter 2023 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
From Novocure
Via Business Wire
Tickers NVCR
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Novocure
Via Business Wire
Tickers NVCR
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Participate in Upcoming Investor Conferences
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports Second Quarter 2023 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Report Second Quarter 2023 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Novocure
Via Business Wire
Tickers NVCR
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports First Quarter 2023 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Report First Quarter 2023 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Kristin Stafford Joins Novocure Board of Directors
From Novocure
Via Business Wire
Tickers NVCR
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.